Research projects into SARS-Cov-2


- SARS-CoV-2 Inhibition, Host Selection and Next-Move Prediction Through High-Performance Computing, funded by the Instituto de Salud Carlos III in the framework of the call “Expressions of interest for the financing of research projects on SARS- Cov-2 and Covid-19 disease” (Dr.
Modesto Orozco).

- 2019 Rapid interaction profiling of drug-nCoV for deep-network-based repurpose learning, funded by H2020 (call H2020-SC1-PHE-CORONAVIRUS-2020). In collaboration with the Helmholtz Zentrum München (coordinator) and INSERM, this action lasts for 3 years (Dr. Patrick Aloy).

- Preclinical development of innovative mRNA / MVA vaccines against SARS-CoV2 (COVARNA) involved IRB Barcelona researcher Núria López-Bigas. It is a consortium led by Dr. Felipe Garcia of IDIBAPS, with the participation of the partners UB, UPF, CNB-CSIC, Universidad Santiago de Compostela and Université Libre de Bruxelles. The project obtained two official sources of funding: the DGRIS from the Department of Health and the ISCIII.  

- ACE-2-derived peptide super-binders with enhanced efficacy for inhibition of SARS-COV-2 infection. Drs. Antonio Zorzano and Manuel Palacín obtained funding in the Fondo-Supera Covid CRUE-Santander call in a project coordinated by the Public University of Navarra.

- Dr. Patrick Aloy’s lab started a collaboration with Amazon Search Science and AI group to develop a computer tool using artificial intelligence that will accelerate the search for drugs against COVID-19.

Thank you!

We would like to thank all those who contributed to our achievements in 2020.
Our hope is to bring biomedical advances to society.
Our goal, to improve people’s quality of life.